Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
|Dengue Virus||Biological: Investigational Vaccine for Dengue Virus Subtype 2 Other: Placebo||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects|
- Immunogenicity of vaccine, as assessed by neutralizing antibody titers [ Time Frame: Measured at 4 and 6 weeks after vaccination ]
- Safety of vaccine, as assessed by the frequency of vaccine-related adverse events (AEs), graded by severity [ Time Frame: Measured throughout study ]
- Number of vaccinees infected with this dengue virus subtype 2 (DEN2) candidate vaccine, as defined by either recovery of vaccine virus from the blood of vaccinated participants and/or by seroconversion to DEN2 [ Time Frame: Measured at Days 28 and 42 ]
- Frequency, quantity, and duration of viremia [ Time Frame: Measured after vaccination ]
- Comparison of infectivity rates, safety, and immunogenicity of a single dose of DEN2 vaccine from this trial to those variables on previous trials [ Time Frame: Measured at study completion ]
|Study Start Date:||February 2010|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Experimental: Dengue Virus Subtype 2 Vaccine
Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
Biological: Investigational Vaccine for Dengue Virus Subtype 2
Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
Other Name: rDEN2/4Δ30
Placebo Comparator: Placebo
Participants will receive a single dose of placebo vaccine.
Subcutaneous injection of placebo
Dengue viruses cause approximately 50 million cases of dengue fever and 1.5 million cases of the more severe diseases dengue hemorrhagic fever (DHS) and dengue shock syndrome (DSS) every year. There are four subtypes of the virus, and infection with one offers no protection from infection by the others. In fact, most cases of DHS and DSS occur in people infected by more than one subtype. In areas of the world where multiple subtypes of dengue are common, vaccines must be developed against each of the subtypes of dengue virus. This study will examine the safety and immune response of an investigational vaccine for preventing dengue virus type 2.
Participation in this study will last about 6 weeks. Participants will be randomly assigned to be injected with either the investigational study vaccine or a placebo. Participants will have a five in six chance of receiving the vaccine. The first study visit will take place on the vaccination day, on which participants will undergo a physical examination, blood draw, and pregnancy test and then receive the vaccine. Participants will be given a thermometer and temperature card and be told to record their temperatures three times per day for 16 days after vaccination. Participants will come to follow-up visits every other day for the 16 days after vaccination and then 3, 4, and 6 weeks after vaccination (Days 21, 28, and 42). Assessments completed during these visits will include a questionnaire about how the participant is feeling, pregnancy test, review of temperature cards, blood draw, and physical exam. Blood drawn will be analyzed to check participants' health, determine the amount of vaccine and antibodies in the blood, test markers in white blood cells and genes, and look for proteins that are important for fighting dengue infection.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01073306
|United States, District of Columbia|
|Johns Hopkins Project SAVE, Center for Immunization Research|
|Washington, District of Columbia, United States, 20037|
|Principal Investigator:||Kawsar Talaat, MD||Johns Hopkins Bloomberg School of Public Health|